PMID- 34667196
OWN - NLM
STAT- MEDLINE
DCOM- 20220125
LR  - 20220125
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Oct 19
TI  - Ameliorative effect of curcumin and zinc oxide nanoparticles on multiple 
      mechanisms in obese rats with induced type 2 diabetes.
PG  - 20677
LID - 10.1038/s41598-021-00108-w [doi]
LID - 20677
AB  - The present study was carried out to investigate the therapeutic effect of 
      synthesized naturally compounds, curcumin nanoparticles (CurNPs) and metal oxide, 
      zinc oxide nanoparticles (ZnONPs) on a high-fat diet (HFD)/streptozotocin 
      (STZ)-induced hepatic and pancreatic pathophysiology in type 2 diabetes mellitus 
      (T2DM) via measuring AKT pathway and MAPK pathway. T2DM rats were 
      intraperitoneally injected with a low dose of 35 mg/kg STZ after being fed by HFD 
      for 8 weeks. Then the rats have orally received treatments for 6 weeks. 
      HFD/STZ-induced hepatic inflammation, reflected by increased phosphorylation of 
      p38-MAPK pathway's molecules, was significantly decreased after nanoparticle 
      supplementation. In addition, both nanoparticles significantly alleviated the 
      decreased phosphorylation of AKT pathway. Further, administration of ZnONPs, 
      CurNPs, conventional curcumin, and ZnSO(4) (zinc sulfate), as well as metformin, 
      effectively counteracted diabetes-induced oxidative stress and inflammation in 
      the internal hepatic and pancreatic tissues. Based on the results of the current 
      study, ZnONPs and CurNPs could be explored as a therapeutic adjuvant against 
      complications associated with T2DM. Both nanoparticles could effectively delay 
      the progression of several complications by activating AKT pathway and 
      down-regulating MAPK pathway. Our findings may provide an experimental basis for 
      the application of nanoparticles in the treatment of T2DM with low toxicity.
CI  - (c) 2021. The Author(s).
FAU - Abdulmalek, Shaymaa
AU  - Abdulmalek S
AD  - Department of Biochemistry, Faculty of Science, Alexandria University, 
      Alexandria, 21511, Egypt.
AD  - Center of Excellency for Preclinical Study (CE-PCS), Pharmaceutical and 
      Fermentation Industries Development Centre, The City of Scientific Research and 
      Technological Applications, SRTA-City, New Borg El-Arab City, Alexandria, Egypt.
FAU - Eldala, Asmaa
AU  - Eldala A
AD  - Department of Biochemistry, Faculty of Science, Alexandria University, 
      Alexandria, 21511, Egypt.
FAU - Awad, Doaa
AU  - Awad D
AD  - Department of Biochemistry, Faculty of Science, Alexandria University, 
      Alexandria, 21511, Egypt.
FAU - Balbaa, Mahmoud
AU  - Balbaa M
AUID- ORCID: 0000-0002-0876-6604
AD  - Department of Biochemistry, Faculty of Science, Alexandria University, 
      Alexandria, 21511, Egypt. mahmoud.balbaa@alexu.edu.eg.
LA  - eng
PT  - Journal Article
DEP - 20211019
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antioxidants)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 5W494URQ81 (Streptozocin)
RN  - 9100L32L2N (Metformin)
RN  - IT942ZTH98 (Curcumin)
RN  - SOI2LOH54Z (Zinc Oxide)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Blood Glucose/drug effects
MH  - Curcumin/*pharmacology
MH  - Diabetes Mellitus, Experimental
MH  - Diabetes Mellitus, Type 2/chemically induced/*drug therapy/metabolism
MH  - Diet, High-Fat/adverse effects
MH  - Hypoglycemic Agents/*pharmacology
MH  - Inflammation/metabolism
MH  - Insulin/metabolism
MH  - Insulin Resistance/physiology
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Metformin/pharmacology
MH  - Nanoparticles/*administration & dosage
MH  - Obesity/*metabolism
MH  - Oxidative Stress/drug effects
MH  - Rats
MH  - Streptozocin/pharmacology
MH  - Zinc Oxide/*pharmacology
PMC - PMC8526574
COIS- The authors declare no competing interests.
EDAT- 2021/10/21 06:00
MHDA- 2022/01/27 06:00
PMCR- 2021/10/19
CRDT- 2021/10/20 06:18
PHST- 2021/06/08 00:00 [received]
PHST- 2021/09/24 00:00 [accepted]
PHST- 2021/10/20 06:18 [entrez]
PHST- 2021/10/21 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/10/19 00:00 [pmc-release]
AID - 10.1038/s41598-021-00108-w [pii]
AID - 108 [pii]
AID - 10.1038/s41598-021-00108-w [doi]
PST - epublish
SO  - Sci Rep. 2021 Oct 19;11(1):20677. doi: 10.1038/s41598-021-00108-w.